Executive management, fractional CEO, and clinical affairs consulting for small and startup life science companies. We are boots on the ground in the US to establish companies, develop successful strategies, execute on customer discovery and work through reimbursement and regulatory requirements.

New Day Ventures is a life science investment firm based in Raleigh, NC. Their investment portfolio is early and mid stage life science companies. I will be reviewing companies and advising in the medical device sector of their portfolio and potential new investments.

NeckCare makes wearable sensors and software that use patented technology to measure and analyze neck mobility and movement control. Our NeckSmart solution provides healthcare professionals and their patients with the tool they need to gain deeper insight into their condition and set on a data-driven journey towards recovery.At NeckCare it is our mission to improve treatment effectiveness of musculoskeletal conditions through development of innovative technology that supports objective assessment, personalized tele-rehabilitation, and compliance monitoring.

Executive management of Voxello. Voxello participates in the $55 billion dollar assistive technology market. Voxello has developed a proprietary "noddle" which interprets voluntary actions, such as an eye blink, or tongue clicking sound, into methods for those who have no other means of communicating to effectively communicate and control devices such as a tablet with speech generation software, environmental controls, and entertainment. There are 3.9 million hospitalized patients that cannot speak or access a nurse call and are 3 times more likely to experience a preventable adverse event as a result. In 2012 the Joint Commission mandated that if effective means of communication could be provided to patients it must be instilled in our hospitals. With the Voxello noddle, we aim to reduce these adverse events while also improving patient satisfaction.We are Voxello, improving communication for better outcomes.

President and principle shareholder of Rives Audio, Inc. Changed the entire way acoustical engineering and design is distributed to residential clients by productizing a service and distributing it through an extensive dealer network. • Marketed Rives Audio through development of many marketing tools from the company’s website, procedures, brochures, and design book which dealers use to sell the company’s services. Resulted in the company becoming the largest provider of residential acoustical engineering and design services with 85 dealers in only two years of existence. • Productized an acoustical engineering design service and distributing through a dealer network, thereby allowing dealers to have a catalog line item for the service. Resulted in attracting over 85 dealers and becoming the world leader in media room designs in two years time. • Designed an innovative audio component (PARC or Parametric Adaptive Room Compensation) system, for very high end audio systems to deal with low frequency problems in the room (caused by the room). Resulted in the PARC winning Absolute Sounds’ Golden Ear award, Stereophile’s Product of the year, and remains a class “A” recommended component by Stereophile. Received US patent (patent # 7,702,113).

Managed clinical affairs team.Managed all research studies.Collected and organized all data for research and development including studies.Conducted studies for FDA submissions. Collaborated with institutions and luminaries for publications and presentations.Developed a top tier medical advisory board including directors from MD Anderson Memorial Sloan Kettering, Albert Einstein and UT Southwestern.Insured GCP compliance for all clinical activities.

Talon Loudspeakers was purchased by Rives Audio in 2007. In 2009 Rives Audio moved all of Talon's operations to Iowa. In 2012 Talon Loudspeakers was spun out of Rives Audio as an LLC. Talon was recently awarded "Best Sound at Show" by Neil Gader of the Absolute Sound for CES 2012.

• Developed phase 1 clinical trials for a functional based optical breast imaging system.• Collaborated in the development of the optical imaging device prototype.

• Created an innovative patented method for using a surgical cutting device which revolutionized large core minimally invasive stereotactic biopsy. Resulted in market share increases for two medical equipment companies (Trex and US Surgical) with revenue of $50 million. (Patent # 5,830,219)• Led a world-class research team for a stereotactic breast biopsy research study. Resulted in a loyal group of luminary physicians which regularly wrote about the system in peer review journals and spoke about the system at mammography conferences. This resulted in greater credibility and overall image of Lorad and increased sales for the system.• Instrumental in the development of the Lorad Prone Stereotactic Breast Biopsy System, the Lorad M-IV, and the early development of the full field digital mammography system.• Inventor of 2 patents in the breast imaging field. Patent 5,706,327: Method and apparatus for mammographic compression. Patent 5,830,219: Apparatus for holding and driving a surgical cutting device using stereotactic mammography guidance.• Managed a stereotactic clinical trial consisting of 10 sites, 10 lead physicians, and over 1000 patients. Resulted in the largest study to date with the most influential physicians in mammography, over 60 peer-reviewed papers, and increased credibility and image in the market place for Lorad. • Guided and conducted initial trial of Full Field Digital Mammography under a 510k application. Resulted in company receiving approval for the protocol conducting trial and submitting trial results to the FDA.• Collaborated with sales, marketing, application specialists and engineering to develop the Lorad M-IV mammography system. This system rapidly became the market leader and remains the market leader still 10 years after its development.Note: This was originally Lorad and was later acquired by Hologic